Remifentanil Analgesia May Lower Postpartum Depression and Boost Birth Experience: Study

A New Look at Labor Pain Relief and Maternal Wellbeing

A recent observational study published in BMC Pregnancy and Childbirth shines a spotlight on the potential psychological benefits of remifentanil analgesia during labor. Conducted at Taleghani Hospital in Tabriz, Iran, this research explores the impact of remifentanil—a short-acting opioid—on postpartum depression and women’s birth experiences.

The Study Design: Comparing Pain Relief Approaches

Researchers followed 200 women who had vaginal births: 100 received remifentanil analgesia during labor (the exposure group), and 100 did not receive any pharmacological pain relief (the non-exposure group). Participants were similar in age, socioeconomic status, and obstetric background. The team used the Edinburgh Postnatal Depression Scale (EPDS) and the Childbirth Experience Questionnaire (CEQ) to assess outcomes 4 to 6 weeks after delivery.

Key Findings: Remifentanil’s Positive Influence

Lower Rates of Postpartum Depression:

Women who received remifentanil had significantly lower depression scores compared to those who had no pain relief. This supports the idea that effective pain management in labor may be protective against postpartum depression.

Enhanced Childbirth Experience:

Not only did the remifentanil group report less depression, but they also described a more positive birth experience. Scores were higher specifically in the domains of “own capacity,” “perceived safety,” and “participation,” suggesting that pain relief helped women feel more in control, safer, and more involved during childbirth.

Professional Support Unchanged:

Interestingly, both groups rated professional support similarly, indicating that the improved experience was likely due to the pain relief itself rather than differences in midwifery or medical care.

Discussion: What Does It Mean for Maternity Care?

This study highlights remifentanil as a promising approach for both improving mothers’ birth experiences and potentially lowering the risk of postpartum depression. While some previous research has shown mixed results regarding pain relief and maternal mental health, this study adds weight to the argument for accessible, effective labor analgesia.

However, the authors note that postpartum depression is a multifactorial condition. Factors such as fear of childbirth, pain perception, and expectations around pain relief—none of which were deeply explored in this study—may also play important roles.

Limitations and Future Directions

The study was observational and followed women only up to 6 weeks postpartum. The authors call for randomized clinical trials with longer follow-up and deeper exploration of related factors to draw more definitive conclusions.

5 Key Takeaways:

Remifentanil analgesia during labor was linked to lower postpartum depression scores.

Women who received remifentanil reported a more positive birth experience.

Key improvements were seen in feelings of control, safety, and participation.

Professional support ratings were similar regardless of pain relief.

Further clinical trials are needed to confirm these results and explore long-term effects.

Citation:

Jorbijarkali FS, Ghanbari-Homaie S, Mirghafourvand M, Rezaei M, Malakouti J. Association of remifentanil analgesia with postpartum depression and birth experience: an observational study. BMC Pregnancy and Childbirth. 2025;25:583. https://doi.org/10.1186/s12884-025-07704-y